HC Wainwright Comments on Evolus’ Q4 Earnings (NASDAQ:EOLS)

Evolus, Inc. (NASDAQ:EOLS) – HC Wainwright lifted their Q4 2024 earnings estimates for Evolus in a research report issued to clients and investors on Wednesday, January 22nd. HC Wainwright analyst D. Tsao now expects that the company will earn $0.00 per share for the quarter, up from their previous forecast of ($0.01). HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Evolus’ Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.11 EPS, FY2026 earnings at $0.87 EPS, FY2027 earnings at $1.63 EPS and FY2028 earnings at $2.89 EPS.

Separately, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Tuesday, January 21st.

Evolus Stock Up 1.5 %

Shares of Evolus stock opened at $14.23 on Friday. The stock has a market capitalization of $901.06 million, a price-to-earnings ratio of -15.64 and a beta of 1.32. Evolus has a twelve month low of $9.25 and a twelve month high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The business’s 50 day simple moving average is $11.79 and its 200-day simple moving average is $13.79.

Hedge Funds Weigh In On Evolus

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Essex Investment Management Co. LLC increased its holdings in shares of Evolus by 0.4% during the third quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock valued at $4,788,000 after purchasing an additional 1,111 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Evolus by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock worth $148,000 after buying an additional 1,291 shares in the last quarter. Creative Planning lifted its stake in shares of Evolus by 23.7% in the 3rd quarter. Creative Planning now owns 15,451 shares of the company’s stock worth $250,000 after acquiring an additional 2,963 shares during the period. Sei Investments Co. increased its stake in shares of Evolus by 9.8% during the second quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock valued at $367,000 after acquiring an additional 3,020 shares during the period. Finally, KBC Group NV bought a new stake in Evolus during the fourth quarter worth approximately $49,000. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.